Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Global Stock · Columbia Threadneedle

Columbia Global Value Fund Columbia Global Value Fund Institutional 3 Class (CEVYX)

Ticker CEVYX · Since 2013-02-28 · · Holdings as of May 31, 2026

Expense ratio
0.77%$77/yr per $10k
5-yr return
+11.3%annualized
1-yr return
+22.0%as of Dec 2025
Net assets
$884.5Mall share classes
Holdings
87

Bottom line

Is CEVYX a good fund? The bottom line

CEVYX is a share class of Columbia Global Value Fund, a managed global stock mutual fund from Columbia Threadneedle.

Its expense ratio is 0.77% — about $77 a year on every $10,000 invested, cheaper than 72% of global stock funds we track.

It returned +22.0% over one year, +11.3% a year over five years, +10.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $885 million in net assets and 87 holdings, its largest position is Alphabet Inc (4.3%) and the top 10 make up 29.2% of the portfolio.

What stands out

  • 5-year return beat 84% of category peers
  • No front-end sales load

Updated Nov 19, 2026

What CEVYX invests in

Columbia Global Value Fund (the Fund) seeks to provide shareholders with growth of capital and income.

Under normal circumstances, the Fund invests at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities of value companies. The Fund considers value companies to be those companies that are either constituents of an index constructed by a third party to identify companies with various characteristics of value companies, or that have a higher book-to-price (B/P) ratio than the median ranked stock within the companys GICS sector, have a higher EBITDA/EV (earnings before interest, taxes, depreciation and amortization-to-enterprise value) or have a lower price-to-earnings ratio than the median ranked stock within the companys GICS sector. The third-party broad-based index currently used to identify value companies is the Russell 3000 Value Index, although the Fund may change the referenced index without prior notice. Equity securities…

From the fund's prospectus (filed Jun 25, 2026).

CEVYX performance

Average annual total returns
1 yr5 yr10 yr
CEVYX+22.0%+11.3%+10.2%
Global Stock median+15.2%+7.6%+9.5%

Source: Fund prospectus, as of Dec 31, 2025

Full CEVYX performance history →

What CEVYX costs

On a $10,000 investment, CEVYX's 0.77% expense ratio costs about $77 a year. The prospectus estimates $954 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.

See the full CEVYX fee table →

CEVYX top 10 holdings

#Holding% of fund
1Alphabet Inc4.31%
2Micron Technology Inc4.25%
3Meta Platforms Inc3.65%
4JPMorgan Chase & Co3.54%
5Shell PLC2.57%
6Bank of America Corp2.32%
7Primo Brands Corp2.29%
8Citigroup Inc2.12%
9Jazz Pharmaceuticals PLC2.07%
10Chubb Ltd2.04%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 29.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to CEVYX

More funds like CEVYX →

CEVYX FAQ

What is the expense ratio of CEVYX?
CEVYX's expense ratio is 0.77%, which works out to about $77 a year for every $10,000 invested. The prospectus estimates total costs of $954 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is CEVYX a good investment?
It depends on your goals, but the data points to: 5-year return beat 84% of category peers; no front-end sales load. This is general information, not personalized advice.
What does CEVYX hold?
CEVYX's largest holdings are Alphabet Inc (4.3%), Micron Technology Inc (4.2%), Meta Platforms Inc (3.6%), JPMorgan Chase & Co (3.5%), Shell PLC (2.6%). It holds 87 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is CEVYX's 5-year return?
CEVYX returned +11.3% a year over the five years ending Dec 31, 2025, and +10.2% a year over ten years. Past performance does not guarantee future results.
Does CEVYX have a sales load?
No. CEVYX has no front-end sales charge.
Who manages CEVYX?
CEVYX is offered by Columbia Threadneedle through Columbia Funds Series Trust II.